SITC's Guide to Managing Immunotherapy Toxicity Best Practices for Managing Side Effects of Cancer Treatment

Image of the book cover for 'SITC's Guide to Managing Immunotherapy Toxicity'
Author: Marc Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi Diab, MD, Peter Hersey, MD, PhD
Publisher: Springer Publishing Company
Publication Date: 2019
ISBN 10: 0826172148
ISBN 13: 9780826172143
eISBN: 9780826172150
Edition: 1st
SITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part One contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with Anti-CTLA4 agents, Anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part Two is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part Two concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of 'financial toxicity' on patients and caregivers. With chapters written by world recognized oncology leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care.
Related Titles